Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Mutations in presenilin 1 (PS1) lead to dominant inheritance of early onset familial Alzheimer disease (FAD). These mutations are known to alter the γ-secretase cleavage of the amyloid precursor protein, resulting in increased ratio of Aβ42/Aβ40 and accelerated amyloid plaque pathology in transgenic mouse models. To investigate the factors that drive the Aβ42/Aβ40 ratio and amyloid pathogenesis and to investigate the possible interactions between wild-type and FAD mutant PS1, which are co-expressed in transgenic animals, we expressed the PS1 M146V knock-in allele either on wild-type PS1 (PS1M146V/+) or PS1 null (PS1M146V/–) background and crossed these alleles with the Tg2576 APP transgenic mice. Introduction of the PS1 M146V mutation on Tg2576 background resulted in earlier onset of plaque pathology. Surprisingly, removing the wild-type PS1 in the presence of the PS1 M146V mutation (PS1M146V/–) greatly exacerbated the amyloid burden; and this was attributed to a reduction of γ-secretase activity rather than an increase in Aβ42. Our findings establish a protective role of the wild-type PS1 against the FAD mutation-induced amyloid pathology through a partial loss-of-function mechanism. Mutations in presenilin 1 (PS1) lead to dominant inheritance of early onset familial Alzheimer disease (FAD). These mutations are known to alter the γ-secretase cleavage of the amyloid precursor protein, resulting in increased ratio of Aβ42/Aβ40 and accelerated amyloid plaque pathology in transgenic mouse models. To investigate the factors that drive the Aβ42/Aβ40 ratio and amyloid pathogenesis and to investigate the possible interactions between wild-type and FAD mutant PS1, which are co-expressed in transgenic animals, we expressed the PS1 M146V knock-in allele either on wild-type PS1 (PS1M146V/+) or PS1 null (PS1M146V/–) background and crossed these alleles with the Tg2576 APP transgenic mice. Introduction of the PS1 M146V mutation on Tg2576 background resulted in earlier onset of plaque pathology. Surprisingly, removing the wild-type PS1 in the presence of the PS1 M146V mutation (PS1M146V/–) greatly exacerbated the amyloid burden; and this was attributed to a reduction of γ-secretase activity rather than an increase in Aβ42. Our findings establish a protective role of the wild-type PS1 against the FAD mutation-induced amyloid pathology through a partial loss-of-function mechanism. The pathological hallmark defining Alzheimer disease (AD) 3The abbreviations used are: AD, Alzheimer disease; FAD, familial Alzheimer disease; Aβ, β-amyloid peptide; APP, amyloid precursor protein; CTF, carboxyl-terminal fragments; PS1, presenilin 1; TBS, Tris-buffered saline; ELISA, enzyme-linked immunosorbent assay; CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid; FL, full-length; PBS, phosphate-buffered saline; Bicine, N,N-bis(2-hydroxyethyl)glycine; BACE1, β-bite APP-cleaving enzyme.3The abbreviations used are: AD, Alzheimer disease; FAD, familial Alzheimer disease; Aβ, β-amyloid peptide; APP, amyloid precursor protein; CTF, carboxyl-terminal fragments; PS1, presenilin 1; TBS, Tris-buffered saline; ELISA, enzyme-linked immunosorbent assay; CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid; FL, full-length; PBS, phosphate-buffered saline; Bicine, N,N-bis(2-hydroxyethyl)glycine; BACE1, β-bite APP-cleaving enzyme. is the deposition of β-amyloid plaques of which the principal components are 40–42-amino acid peptides referred to as the β-amyloid peptides (Aβ), which are derived by proteolytic cleavages of the amyloid precursor protein (APP). APP is processed by at least three proteinases known as α-, β-, and γ-secretases. Both α- and β-secretases (BACE1) process APP in the extracellular domain with α-secretase cleavage occurring inside the Aβ domain and BACE1 at the amino terminus of Aβ. These proteolytic events generate APP carboxyl-terminal fragments (CTF), which serve as substrates for subsequent γ-secretase processing, producing either p3 (product of α- and γ-secretases) or Aβ peptides (product of BACE1 and γ-secretase) (reviewed in Ref. 1Wilquet V. De Strooper B. Curr. Opin. Neurobiol. 2004; 14: 582-588Crossref PubMed Scopus (200) Google Scholar). The γ-secretase activity is executed by a high molecular weight complex of which presenilin 1 (PS1) is an essential component (reviewed in Ref. 2Iwatsubo T. Curr. Opin. Neurobiol. 2004; 14: 379-383Crossref PubMed Scopus (150) Google Scholar). As such, inhibition of PS1 leads to the accumulation of APP-CTF (3De Strooper B. Saftig P. Craessaerts K. Vanderstichele H. Guhde G. Annaert W. Von Figura K. Van Leuven F. Nature. 1998; 391: 387-390Crossref PubMed Scopus (1532) Google Scholar, 4Yu H. Saura C.A. Choi S.Y. Sun L.D. Yang X. Handler M. Kawarabayashi T. Younkin L. Fedeles B. Wilson M.A. Younkin S. Kandel E.R. Kirkwood A. Shen J. Neuron. 2001; 31: 713-726Abstract Full Text Full Text PDF PubMed Scopus (217) Google Scholar, 5Feng R. Rampon C
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Self-citationMembrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., et al. (2000) · Nature · doi:10.1038/35015085 · Cited by 866
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637
Self-citationGuo, Q., Fu, W., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., & Mattson, M. P. (1999) · Nature Medicine · doi:10.1038/4789 · Cited by 489
Song, W., Nadeau, P., Yuan, M., Yang, X., Shen, J., & Yankner, B. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6959 · Cited by 362
Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212
Self-citationSaura, C. A., Chen, G., Malkani, S., Choi, S.-Y., Takahashi, R. H., Zhang, D., Gouras, G. K., Kirkwood, A., Morris, R. G. M., & Shen, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1247-05.2005 · Cited by 157
Siman, R., Reaume, A. G., Savage, M. J., Trusko, S., Lin, Y.-G., Scott, R. W., & Flood, D. G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08717.2000 · Cited by 133
Cited by
The secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Animal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676
Lian, H., Litvinchuk, A., Chiang, A. C.-A., Aithmitti, N., Jankowsky, J. L., & Zheng, H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2117-15.2016 · Cited by 597
Self-citationKuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.211 · Cited by 532
“Interesting in vivo studies have further shown that increased levels of Ab40 peptides in the brain actually might have a protective effect (Wang et al, 2006; Kim et al, 2007).”
BackgroundThe mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
“Whereas A b 40 appears to act protectively in various toxicity assays (Wang et al , 2006; Kim et al , 2007), longer A b peptides promote aggregation and neurotoxicity (McGowan et al , 2005).”
Metadata
- Authors
- Wang, R., Wang, B., He, W., & Zheng, H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 281
- Issue
- 22
- Pages
- 15330-15336
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2074569125
- Cited by
- 73
- References
- 14
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.